Carla Casulo MD

Hematologic Oncology

Professor, Medicine, University of Rochester School of Medicine & Dentistry

601 Elmwood Ave# BoxRochester, NY 14642
Phone+1 585-275-5863
Fax+1 585-273-1051

Dr. Casulo is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Casulo's full profile Already have an account?

Summary

Carla Casulo, MD, is an internationally renowned lymphoma expert based in Rochester, NY. Her research focuses on follicular lymphoma, large datasets, real world outcomes, clinical trials, cancer research training and mentoring. She completed her internal medicine residency at Yale-New Haven Medical Center and her fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center. She currently serves as a Professor at the Wilmot Cancer Center. Dr. Casulo has led over 100 publications in top tier and highly reputable journals and is actively involved in clinical trials focused on lymphoma treatments. She has been recognized for highest clinical trial enrollment across the Wilmot Cancer Institute. Dr Casulo has received several awards for clinical care, mentoring and career development. She is a member of the Women in Lymphoma Steering Committee and is immediate past chair. Dr Casulo was previous editorial board member for Blood journal and currently serves as editorial board member for Blood Advances.

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Gastroenterology, 2021 - 2027
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2012
Yale-New Haven Medical CenterResidency, Internal Medicine, 2004 - 2008
State University of New York Downstate Medical Center College of MedicineClass of 2004

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 2008 - 2027
CT State Medical License 2007 - 2008
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Clinical Trial Enrollment Across Wilmot Cancer Institute Wilmot Cancer Institute, 2025-2026
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
COMPLETED
PHASE1
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
COMPLETED
NA
A Phase II Study of Doxycycline in Relapsed NHL
TERMINATED
PHASE2

Publications & Presentations

PubMed

Five-year results of short-course brentuximab vedotin combined with chemotherapy and radiation in early stage, unfavorable Hodgkin lymphoma.
Robert Stuver, Esther Drill, Laure Michaud, Carla Casulo, Ranjana H Advani
Haematologica. 2026-10-01
Patterns of care, outcomes, and prognostics for transformed follicular lymphoma in the rituximab era.
Jonathan R Day, Melissa C Larson, Carla Casulo, Urshila Durani, Yucai Wang
Haematologica. 2026-09-24
2 citations
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.
Jamie E Flerlage, Dennis A Eichenauer, Michael Fuchs, Sylvia Hartmann, Hans T Eich
Blood Advances. 2026-08-11

Journal Articles

Venetoclax plus R- or G-CHOP in Non-Hodgkin Lymphoma: Results from the CAVALLI Phase 1b Trial
Andrew D Zelenetz, Andre Goy, Carla Casulo, Blood

Abstracts/Posters

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
Carla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...
Carla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Carla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The effect of duvelisib, a dual inhibitor of PI3K-I on components of the tumor microenvironment in previously untreated follicular lymphoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

From Diagnosis to Remission: Survivors Shine Light on Blood Cancer Awareness MonthSeptember 28th, 2025
Hodgkin Lymphoma Treatment: Boosting New Options for Young People with Advanced DiseaseJune 4th, 2023
POD24 Predicts Poor Prognosis in Follicular LymphomaDecember 1st, 2021